Why Aduhelm, a new Alzheimer’s cure, is just not reaching lots of people : Quick Wave : NPR

Scan Of The Mind Of A Individual Afflicted By Alzheimer’s Ailment Axial Portion. The Meals and Drug Administration accredited aducanamab, the to start with drug to affect the underlying illness procedures associated with Alzheimer’s in June.

BSIP/Common Photos Team through Getty

hide caption

toggle caption

BSIP/Universal Photos Group by way of Getty

Scan Of The Mind Of A Affected individual Affected By Alzheimer’s Ailment Axial Part. The Foods and Drug Administration authorized aducanamab, the 1st drug to affect the fundamental ailment procedures affiliated with Alzheimer’s in June.

BSIP/Common Visuals Team by means of Getty

Aduhelm, regarded generically as aducanumab, is the very first drug to in fact have an affect on the fundamental disease method connected with Alzheimer’s. Still gross sales have been confined, and the drug is reaching quite handful of people — at minimum so far. It is high-priced, risky and most likely carrying out small to increase patients’ lives. NPR science correspondent Jon Hamilton explains why physicians and sufferers aren’t thrilled about the new drug and what it could suggest for long term Alzheimer’s medicine.

More links:

You can generally arrive at the clearly show by emailing [email protected]

This episode was edited by Sara Sarasohn, produced by Rebecca Ramirez and fact-checked by Margaret Cirino. Neil Tevault was the audio engineer.